IMPEDIMED LIMITED — Capital/Financing Update 2017

Apr 25, 2017

==> picture [226 x 43] intentionally omitted <==

26 April 2017

ASX ANNOUNCEMENT

– APPENDIX 4C Quarter Ended 31 March 2017

Brisbane, Australia - ImpediMed Limited (ASX: IPD) a global provider of medical technology to measure, monitor and manage fluid status and body composition, today released its Appendix 4C – Quarterly cash flow report for the period ended 31 March 2017.

Total revenue for the period was $1.6 million, including lymphoedema sales of $1.1 million. Net operating cash outflow for the quarter was $7.0 million. Cash receipts from customers for the quarter were $1.1 million and cash on hand as of 31 March 2017 was $62.2 million.

Highlights for the past quarter include:

• Trained 16 new L-Dex® accounts in Q1 of CY2017; targeting a total of 72 new L-Dex accounts for CY2017 in the second year since commercial launch;

• 920 patients enrolled to date in randomised lymphoedema (LE) post-approval clinical trial;

• Added Columbia University Medical Center to the LE post-approval clinical trial;

• First shipment of SOZO™ to Scripps Health for chronic heart failure (CHF) clinical study. The site will use SOZO™ in the initial study for monitoring patients with CHF in a clinical setting, in order to provide real-world data;

• Mr Don Williams and Mr Amit Patel appointed to the Board of Directors as USbased Non-Executive Directors.

“We continue to see strong uptake of L-Dex, with a total of 88 sites now signed and trained since full commercial launch. This provides a strong foundation of top-tier cancer centres across the US using L-Dex in their high-risk patient programs. We expect to see widespread routine use of L-Dex at these sites as we introduce L-Dex readings via SOZO™ into clinical practice and as we secure private payor reimbursement, following the publication of first data from our large post-approval trial”, said Richard Carreon, Managing Director and CEO of ImpediMed.

“We also continue to make excellent progress in readying SOZO™ for clinical studies and regulatory approval/clearance. Following rigorous safety and performance testing, the first devices have been shipped to Scripps Health and Vanderbilt for use in CHF and LE studies using SOZO™.”

Investor Conference Call

Investors are invited to join a conference call with CEO and Managing Director, Richard Carreon, at 9.15am AEST on Wednesday 26[th] April, 2017.

For those who have pre-registered for the call please use the PIN number that has been provided.

Alternatively, the following dial in details may be used:

Conference ID Number: 138746

Australia Toll Free: 1 800 558 698 Alternate Australia Toll Free: 1 800 809 971 Australia Local: 02 9007 3187 New Zealand Toll Free: 0800 453 055 Belgium: 0800 72 111 Canada: 1855 8811 339 France: 0800 913 848 Germany: 0800 182 7617 Hong Kong: 800 966 806 India: 0008 0010 08443 Indonesia: 001 803 019 3275 Ireland: 1800 948 625 Italy: 800 793 500 Japan: 0053 116 1281 Malaysia: 1800 816 294 Singapore: 800 101 2785 United Kingdom: 0800 051 8245 United States: (855) 881 1339

Richard Carreon Managing Director & CEO

For further information, contact:

Richard Carreon, ImpediMed Managing Director & CEO Morten Vigeland, ImpediMed CFO T: +1 (760) 585-2100

Media and Investor Contacts:

In Australia:

Kyahn Williamson, WE Buchan T: +61 3 9866 4722 E: kwilliamson@buchanwe.com.au

About ImpediMed

Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif. and Bloomington, Minn., ImpediMed is the world leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status in patients. ImpediMed has the first medical device with FDA clearance in the U.S. to aid healthcare professionals to clinically assess unilateral lymphoedema of the arm and leg in women and the leg in men. For more information, visit www.impedimed.com.